Wharton’s Jelly Mesenchymal Stem Cell Administration Improves Quality of Life and Self-Sufficiency in Children with Cerebral Palsy: Results from a Retrospective Study

Table 7

Treatment efficacy in subgroups identified on the basis of maximum total cell dose per kilogram of body mass during the whole treatment course.

Maximum total dose (×10^6/kg)	N	Average QoL response per one administration after following administrations; ( chi^2 with Yates correction = not significant)					Developmental breakthrough; ( chi^2 with Yates )						Proportion of patients with developmental breakthrough
		<1				≥4	0	1	2	3	4	5
≤3.23 (<Q1)	14	4	5	4	0	1	12	2	0	0	0	0	0%
3.23-≤4.65 (Q1-Q2)	13	7	2	2	2	0	7	2	2	1	1	0	15.4%
4.65-≤5.93 (Q2-Q3)	13	7	3	1	2	0	8	0	1	1	3	0	30.8%
>5.93 (>Q3)	14	1	7	6	0	0	6	1	0	5	2	0	50%

QoL: quality of life; Q: quartile. The highest improvement in quality of life between two consecutive assessments. Cells marked in bold represent categorization used to Yates’ chi-square test.